HK1059038A1 - Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression - Google Patents

Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression

Info

Publication number
HK1059038A1
HK1059038A1 HK04101904A HK04101904A HK1059038A1 HK 1059038 A1 HK1059038 A1 HK 1059038A1 HK 04101904 A HK04101904 A HK 04101904A HK 04101904 A HK04101904 A HK 04101904A HK 1059038 A1 HK1059038 A1 HK 1059038A1
Authority
HK
Hong Kong
Prior art keywords
integrin expression
angionegesis
inhibition
inhibitor mediated
examining effect
Prior art date
Application number
HK04101904A
Other languages
English (en)
Inventor
Naoto Ono
Taro Senba
Naoko Hata
Yasuhiro Funahashi
Toshiaki Wakabayashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of HK1059038A1 publication Critical patent/HK1059038A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK04101904A 2001-02-21 2004-03-16 Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression HK1059038A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21
PCT/JP2002/001562 WO2002066073A1 (fr) 2001-02-21 2002-02-21 Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine

Publications (1)

Publication Number Publication Date
HK1059038A1 true HK1059038A1 (en) 2004-06-18

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04101904A HK1059038A1 (en) 2001-02-21 2004-03-16 Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression
HK07106835A HK1099363A1 (en) 2001-02-21 2007-06-26 Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK07106835A HK1099363A1 (en) 2001-02-21 2007-06-26 Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Country Status (12)

Country Link
US (1) US7122318B2 (zh)
EP (2) EP1362601B8 (zh)
JP (1) JP4255285B2 (zh)
KR (1) KR20030080013A (zh)
CN (2) CN100384482C (zh)
AT (2) ATE350660T1 (zh)
AU (1) AU2002233677B2 (zh)
CA (1) CA2438427C (zh)
DE (2) DE60217300T2 (zh)
ES (2) ES2317368T3 (zh)
HK (2) HK1059038A1 (zh)
WO (1) WO2002066073A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317368T3 (es) 2001-02-21 2009-04-16 EISAI R&D MANAGEMENT CO., LTD. Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de la integrina.
EP1430894A4 (en) * 2001-09-05 2007-12-12 Eisai R&D Man Co Ltd LYMPHOCYTE ACTIVATION INHIBITOR AND REMEDY FOR AUTOIMMUNE DISEASE
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2006090921A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物のリンパ球活性化抑制作用
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
AU683492B2 (en) * 1993-09-10 1997-11-13 Eisai R&D Management Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
DK0889876T3 (da) * 1996-03-29 2001-09-24 Searle & Co Meta-substituerede phenylensulfonamidderivater
JP2000516201A (ja) * 1996-05-31 2000-12-05 ザ スクリップス リサーチ インスティテュート 血管形成阻害方法及び血管形成阻害に有用な組成物
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
EP1258252B1 (en) * 2000-02-03 2010-04-21 Eisai R&D Management Co., Ltd. Integrin expression inhibitors
ES2317368T3 (es) 2001-02-21 2009-04-16 EISAI R&D MANAGEMENT CO., LTD. Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de la integrina.

Also Published As

Publication number Publication date
CN101025419A (zh) 2007-08-29
US20040132783A1 (en) 2004-07-08
EP1742052B1 (en) 2008-10-29
ES2317368T3 (es) 2009-04-16
CN1620313A (zh) 2005-05-25
AU2002233677B2 (en) 2005-01-06
WO2002066073A1 (fr) 2002-08-29
JPWO2002066073A1 (ja) 2004-06-17
DE60217300D1 (de) 2007-02-15
HK1099363A1 (en) 2007-08-10
DE60229676D1 (de) 2008-12-11
CA2438427A1 (en) 2002-08-29
US7122318B2 (en) 2006-10-17
JP4255285B2 (ja) 2009-04-15
ATE350660T1 (de) 2007-01-15
EP1362601B8 (en) 2007-02-28
EP1362601A4 (en) 2005-07-06
KR20030080013A (ko) 2003-10-10
ES2280502T3 (es) 2007-09-16
CA2438427C (en) 2011-04-12
CN100384482C (zh) 2008-04-30
EP1742052A1 (en) 2007-01-10
DE60217300T2 (de) 2007-10-04
ATE412895T1 (de) 2008-11-15
EP1362601B1 (en) 2007-01-03
EP1362601A1 (en) 2003-11-19

Similar Documents

Publication Publication Date Title
HK1099363A1 (en) Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
EP1287839A3 (de) Messvorrichtung und -verfahren zur Bestimmung von Parametern medizinischer Flüssigkeiten
WO2003084382A3 (en) Assuring quality of breast impedance measurements
BR0315287A (pt) Método para determinar a exatidão de um sensor de pressão em um cassete cirúrgico
WO2004103145A3 (en) Method for pre treatment verification in radiation therapy
FI20000417A (fi) Ihmiseen liittyvä mittausarviointi
DE60124736D1 (de) Vorrichtung zur messung des abschnittsweisen volumens und der elektrischen parallelleitfähigkeit einer herzkammer oder eines blutgefässes
WO2000062070A3 (en) Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
DE69920940D1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
TW374131B (en) A data collection apparatus
WO2006056907A3 (en) Depression detection system
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
DE60035174D1 (de) Invasives verfahren zur in vivo analytvermessung
WO2004113912A8 (en) System and method for determining a temperature during analysis of biological fluid
EP2117422A4 (en) METHOD AND SYSTEM FOR DETERMINING A CEREBROVASCULAR AUTOREGULATION STATE OF A PATIENT
WO2008069881A3 (en) Gene expression profiling for identification, monitoring and treatment of melanoma
WO2002091910A3 (en) Blood flow monitor for shock and resuscitation
WO2003015810A1 (fr) Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale
SE0102919D0 (sv) Medical device
DE69533319D1 (de) Messung des schwellwertes bei atemfühlern
DE50213952D1 (de) Sensoranordnung
WO2004099756A3 (en) Zero corrected optical blood analyte detector
ATE335434T1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
Kim et al. A comparison of the implant stability among various implant systems: clinical study
MXPA05006804A (es) Identificacion, monitoreo y tratamiento de enfermedad infecciosa y caracterizacion de condiciones inflamatorias relacionadas con enfermedad infecciosa usando perfiles de expresion genica.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140221